MedPageToday
MedPage Today) — Trastuzumab deruxtecan (Enhertu, T-DXd) therapy produced “substantial and durable” overall and intracranial clinical activity in patients with HER2-positive advanced breast cancer, according to data from the DESTINY-Breast12…
Read More
Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets
Elroy Wiers
13:39
MedPage Today) — Trastuzumab deruxtecan (Enhertu, T-DXd) therapy produced “substantial and durable” overall and intracranial clinical activity in patients with HER2-positive advanced breast cancer, according to data from the DESTINY-Breast12…
